The application is supported by data from the phase 2b/3 HPTN 083 and HPTN 084 trials, which evaluated the efficacy and safety of Apretude for HIV PrEP. The Food and Drug Administration (FDA) has ...
In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, seven participants contracted the virus despite receiving their ...
Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds ...
The Food and Drug Administration (FDA) has approved the first injectable treatment for HIV pre-exposure prophylaxis, providing another option to help individuals at-risk avoid sexually transmitted HIV ...
The world's first injectable medication to reduce the risk of acquiring HIV has been approved by the Food and Drug Administration (FDA), the agency announced Monday (Dec. 20). The injectable drug — ...
An injectable drug to prevent HIV provides a substantial benefit, according to updated recommendations from the U.S. Preventive Services Task Force (USPSTF). The new recommendations for preexposure ...
The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention. The shots, which are administered by a ...
Add Yahoo as a preferred source to see more of our stories on Google. In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, ...
(The Hill) — The Food and Drug Administration (FDA) has approved the first injectable treatment for HIV pre-exposure prophylaxis, providing another option to help individuals at-risk avoid sexually ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results